Search our Database of Scientific Publications and Authors

I’m looking for a

    7033 results match your criteria Thyroid Medullary Carcinoma

    1 OF 141

    Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
    Cancer Biol Ther 2018 Feb 14. Epub 2018 Feb 14.
    a B Department of Propaedeutic Surgery , Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens , Greece.

    Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update.
    Endokrynol Pol 2018 ;69(1):34-74
    Nuclear Medicine and Endocrine Oncology Department; M.Sklodowska-Curie Memorial Institute - Cancer Center, Gliwice Branch, Wybrzeze AK 15, 44-100 Gliwice, Poland; Zakład Medycyny Nuklearnej i Endokrynologii Onkologicznej, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach, Wybrzeże AK 15, 44-100 Gliwice, Poland.
    Significant advances have been made in thyroid can-cer research in recent years, therefore relevant clinical guidelines need to be updated. The current Polish guidelines "Diagnostics and Treatment of Thyroid Carcinoma" have been formulated at the "Thyroid Cancer and Other Malignancies of Endocrine Glands" conference held in Wisła in November 2015 [1]. Read More

    INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors.
    Am J Surg Pathol 2018 Feb 12. Epub 2018 Feb 12.
    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.
    The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. Read More

    LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
    Int J Oncol 2018 Feb 9. Epub 2018 Feb 9.
    Oncology Research Laboratory, Department of Radiation Sciences, Umeå University, SE-90187 Umeå, Sweden.
    Papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) are characterized by genomic rearrangements and point mutations in the proto-oncogene RET. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a suppressor of various receptor tyrosine kinases, including RET. LRIG1 expression levels are associated with patient survival in many cancer types. Read More

    Letter to the Editor regarding the paper by N. Azzam et al. 'Germline polymorphisms on RET proto-oncogene involved in medullary thyroid carcinoma in a Druze family'.
    Eur J Cancer 2018 Feb 9. Epub 2018 Feb 9.
    Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, DK-5000 Odense, Denmark; Department of Clinical Genetics, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark. Electronic address:

    Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.
    Ann Surg Oncol 2018 Feb 9. Epub 2018 Feb 9.
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Background: No guidelines exist regarding physicians' duty to inform former patients about novel genetic tests that may be medically beneficial. Research on the feasibility and efficacy of disseminating information and patient opinions on this topic is limited.

    Methods: Adult patients treated at our institution from 1950 to 2010 for medullary thyroid cancer, pheochromocytoma, or paraganglioma were included if their history suggested being at-risk for a hereditary syndrome but genetic risk assessment would be incomplete by current standards. Read More

    Clinico-pathological and prognostic findings on 27 cases of medullary thyroid carcinoma.
    Tunis Med 2017 Feb;95(2):97-102
    Introduction: Medullary thyroid carcinoma is a rare tumor accounting for less than 10% of thyroid neoplasm. This tumor is characterized by important histological polymorphism which makes morphological diagnosis difficult and immunohistochemical study often necessary.

    Objective: We aim to perform a retrospective review of clinical and pathological characteristics of medullary carcinoma. Read More

    Apatinib-treated advanced medullary thyroid carcinoma: a case report.
    Onco Targets Ther 2018 19;11:459-463. Epub 2018 Jan 19.
    Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
    Medullary thyroid carcinoma (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. Neither radiotherapy nor chemotherapy has demonstrated durable objective responses in patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine kinase inhibitors recently approved by the US Food and Drug Administration, which are not affordable for most Chinese patients. Read More

    Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma - An Israeli Multicenter Study.
    Thyroid 2018 Feb 5. Epub 2018 Feb 5.
    Hadassah-Hebrew University Medical Center, Neuroendocrine Tumor Unit, Endocrinology & Metabolism Service , P.O.B. 12000, Jerusalem , Jerusalem, Israel , 91120 ;
    Background: The widespread use of neck sonography in recent years has led to a dramatic increase in the detection of thyroid cancer, accompanied by changes in the clinicopathological features of the disease. However, small papillary carcinomas account for the bulk of this increase, while little is known about temporal changes in medullary thyroid carcinoma (MTC). The aim of this study was to evaluate trends in the presentation, treatment, and outcome of MTC. Read More

    [A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
    Zhonghua Nei Ke Za Zhi 2018 Feb;57(2):134-137
    Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
    Multiple endocrine neoplasia type 2A (MEN2A) is a hereditary syndrome. Here, two different RET proto-oncogen mutation were identified from family members of two MEN2A pedigrees by genetic screening. One RET mutations were found at codons 1893 and 1895 in exon 11 (1893-1895delCGA) from pedigree 1, which is a novel mutation, the other occurs at codon 634 (Cys634Arg) in exon 11 from pedigree 2. Read More

    Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.
    J Endocrinol Invest 2018 Feb 2. Epub 2018 Feb 2.
    Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, P.O. Box 23462, 1683, Nicosia, Cyprus.
    Purpose: Multiple endocrine neoplasia type 2 (MEN2) affects patients with RET proto-oncogene mutations. This cohort study refers to patients who were diagnosed with familial medullary thyroid carcinoma (MTC) and underwent RET genetic testing in Cyprus between years 2002 and 2017.

    Methods And Patients: Forty patients underwent RET testing by Sanger sequencing of exons 10-11 and 13-16. Read More

    Contrast-enhanced ultrasound diagnosis of hepatic metastasis of concurrent medullary-papillary thyroid carcinoma: A case report.
    Medicine (Baltimore) 2017 Dec;96(50):e9065
    Department of Pathology, The West China Hospital of Sichuan University, Chengdu, China.
    Rationale: Co-occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same thyroid gland with liver metastasis is a rare condition. To our knowledge, the utility of contrast-enhanced ultrasound (CEUS) to diagnose it is much less.

    Patient Concerns: A 33-year-old female was referred to our hospital due to the increase in plasma calcitonin concentration and carcino-embryonic antigen 12 months after her total thyroidectomy. Read More

    Pycnodysostosis with novel gene mutation and sporadic medullary thyroid carcinoma: A case report.
    Medicine (Baltimore) 2017 Dec;96(50):e8730
    Department of Endocrinology and Diabetes.
    Rationale: Pycnodysostosis is a rare autosomal recessive skeletal dysplasia caused by a mutation in the cathepsin K encoded by cathepsin K gene (CTSK). Medullary thyroid carcinoma (MTC) is also a relatively rare type of primary thyroid carcinoma.

    Patient Concerns: A 31-year-old woman presenting a short stature and a palpable nodule in the front of her neck that had gradually increased in size during the last 2 years was referred to our department. Read More

    Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review.
    Medicine (Baltimore) 2017 Dec;96(50):e8704
    Department of Oncology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
    Rationale: Medullary thyroid carcinoma (MTC) is a rare type thyroid carcinoma originating from the thyroid parafollicular cells (C cells). Chemotherapy has a limited efficacy for treating persistent or recurrent MTC.

    Patient Concerns: A 46-year-old woman who underwent thyroidectomy for MTC in December 2007. Read More

    Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.
    Virchows Arch 2018 Feb 1. Epub 2018 Feb 1.
    Service d'Endocrinologie, Hôpital Huriez, CHRU de Lille, 59037, Lille, France.
    Lymph node involvement (LNI) is one of the most important prognostic factors for poor survival in medullary thyroid carcinoma (MTC). At diagnosis, LNI is found in over 50% of sporadic MTCs, and especially in large tumours. Cervical lymph node dissection is therefore mandatory during MTC surgery. Read More

    Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases.
    Oncol Lett 2018 Jan 1;15(1):672-676. Epub 2017 Nov 1.
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
    Brain metastases from non-medullary thyroid carcinoma (NMTC) are rare, with a reported frequency of ~1%, and patient survival time is <1 year after diagnosis. The optimal management of brain metastases in this setting continues to be debated. The aim of the present study was to evaluate a series of patients with brain metastases from NMTC attending a single tertiary medical center. Read More

    Modifying impact ofgene haplotypes on medullary thyroid carcinoma clinical course.
    Endocr Relat Cancer 2018 Jan 31. Epub 2018 Jan 31.
    R Słomski, -, Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Poznan, Poland.
    The clinical course of medullary thyroid carcinoma (MTC) associated with the MEN2A syndrome as well as of sporadic MTC shows considerable heterogeneity. The disease picture varies between the sameproto-oncogene mutation carriers but also among sporadic MTC patients with nogerminal mutations, which suggests the involvement of additional modulators of the disease. However, genetic factors responsible for this heterogeneity of the MTC clinical course remain still unknown. Read More

    Preimplantation genetic diagnosis of multiple endocrine neoplasia type 2A using informative markers identified by targeted sequencing.
    Thyroid 2018 Jan 29. Epub 2018 Jan 29.
    1. The International Peace Maternity & Child Health Hospita , Shanghai Jiao Tong University School of Medicine , shanghai, China , 200030 ;
    Background: The revised guidelines for the management of medullary thyroid carcinoma recommend that genetic counseling regarding reproductive options, including preimplantation genetic diagnosis (PGD), be considered for all RET mutation carriers of reproductive age to avoid the transmission of multiple endocrine neoplasia type 2 (MEN2). However, the high complexity and cost of PGD have hindered its widespread use. Thus, it is necessary to establish a simple and relatively inexpensive method to facilitate the PGD of MEN2. Read More

    Demographic and Clinical Features of Thyroid Carcinomas in Republic of Macedonia (1999-2010).
    Open Access Maced J Med Sci 2017 Dec 17;5(7):1005-1010. Epub 2017 Oct 17.
    Institute of Pathology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
    Background: Thyroid carcinomas (TC) are the most common endocrine malignancies. In some parts of the world, the incidence of TCs has increased over the past few decades, especially in females according to some studies.

    Aim: We have set as the objective for our study to analyse the demographic, ultrasound features, thyroid hormonal status and frequency of thyroid carcinomas in the Republic of Macedonia according to histopathological type. Read More

    A whole-animal platform to advance a clinical kinase inhibitor into new disease space.
    Nat Chem Biol 2018 Mar 22;14(3):291-298. Epub 2018 Jan 22.
    Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
    Synthetic tailoring of approved drugs for new indications is often difficult, as the most appropriate targets may not be readily apparent, and therefore few roadmaps exist to guide chemistry. Here, we report a multidisciplinary approach for accessing novel target and chemical space starting from an FDA-approved kinase inhibitor. By combining chemical and genetic modifier screening with computational modeling, we identify distinct kinases that strongly enhance ('pro-targets') or limit ('anti-targets') whole-animal activity of the clinical kinase inhibitor sorafenib in a Drosophila medullary thyroid carcinoma (MTC) model. Read More

    Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
    Am J Hematol 2018 Jan 20. Epub 2018 Jan 20.
    Seoul National University Hospital, Seoul, South Korea.
    Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm, open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced malignancies other than NSCLC were to receive a starting dose of crizotinib 250 mg twice daily. Read More

    Preoperative Clinical and Sonographic Predictors for Lateral Cervical Lymph Node Metastases in Sporadic Medullary Thyroid Carcinoma.
    Thyroid 2018 Feb 15. Epub 2018 Feb 15.
    1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
    Background: Total thyroidectomy and cervical lymph node (LN) dissection is generally recommended in patients with medullary thyroid carcinoma (MTC). However, there is no clear evidence for whom to perform prophylactic lateral neck dissection in MTC patients without evident lateral cervical lymph node (LCLN) metastasis in preoperative images. This study evaluated the preoperative features for predicting the LCLN metastasis of MTC. Read More

    Non-mammalian models of multiple endocrine neoplasia type 2.
    Endocr Relat Cancer 2018 Feb;25(2):T91-T104
    Department of Cell Developmental and Regenerative Biology, School of Biomedical Sciences, Icahn School of Medicine, New York, New York, USA
    Twenty-five years ago, RET was identified as the primary driver of multiple endocrine neoplasia type 2 (MEN2) syndrome. MEN2 is characterized by several transformation events including pheochromocytoma, parathyroid adenoma and, especially penetrant, medullary thyroid carcinoma (MTC). Overall, MTC is a rare but aggressive type of thyroid cancer for which no effective treatment currently exists. Read More

    Recent advances in the biology and therapy of medullary thyroid carcinoma.
    F1000Res 2017 28;6:2184. Epub 2017 Dec 28.
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD, 21287, USA.
    Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. Read More

    Small cell medullary thyroid carcinoma: A diagnostic dilemma.
    Indian J Pathol Microbiol 2017 Oct-Dec;60(4):562-564
    Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
    Small cell variant of medullary thyroid carcinoma (MTC) is a rare variant. In the past, primary thyroid lymphomas were thought to be small cell MTC (SCMTC). However, with the advent of immunohistochemistry, it was realized that SCMTC is rare. Read More

    Do you want to participate in a clinical study as a healthy control? - Risk or benefit?
    World J Clin Cases 2017 Dec;5(12):437-439
    Department of Internal Medicine, Kantonsspital Aarau, Aarau 5000, Switzerland.
    A healthy woman volunteered to participate as "healthy control" in a study. An increased level of procalcitonin (PCT) was detected and remained elevated on follow-up measurements. As calcitonin levels were elevated as well, thyroid ultrasound was performed which revealed nodes in both thyroid lobes, one of them showing metabolic activity in positron emission tomography-computed tomography scan. Read More

    A Collision Tumor Involving a Primary Leiomyosarcoma of the Lower Extremity and a Metastatic Medullary Thyroid Carcinoma: A Case Report.
    JBJS Case Connect 2017 Oct-Dec;7(4):e90
    Departments of Radiology (J.S.W.) and Orthopaedics (M.E.A.) and Divisions of Hematology/Oncology (D.S.) and Anatomic Pathology (J.D.G.), Beth Israel Deaconess Medical Center, Boston, Massachusetts.
    Case: A 49-year-old man presented with a rapidly growing thigh mass. Histologic analyses demonstrated separate regions that were consistent with a collision tumor composed of a primary leiomyosarcoma and a metastatic medullary thyroid carcinoma. After responding to chemotherapy, the patient underwent resection of the tumor and a total thyroidectomy; he was disease-free 9 years after the diagnosis. Read More

    High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    World J Surg Oncol 2017 Dec 29;15(1):230. Epub 2017 Dec 29.
    School of Medicine, Taipei Medical University and Fu Jen Catholic University, New Taipei City, Taiwan.
    Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers, and its value in the surveillance of post-operative colorectal cancer is well established. Fluorodeoxyglucose-positron emission tomography (FDG-PET) has been clinically used in colorectal cancer imaging including preoperative staging, evaluation of therapeutic response, detection of disease recurrence, and investigation of unexplained rising tumor markers.

    Case Presentation: We report a case of resected colorectal cancer presented with rising CEA levels in 5 years, and FDG-PET revealed no definitive evidence of recurrence except abnormal focal FDG uptake in the right thyroid lobe. Read More

    Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Pharmacol Res 2018 Feb 25;128:1-17. Epub 2017 Dec 25.
    Department of Pediatrics, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111-1552, United States. Electronic address:
    RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-α (GFRα) co-receptors (GFRα1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. Read More

    Gene Fusions in Thyroid Cancer.
    Thyroid 2018 Feb;28(2):158-167
    1 Research Centre for Medical Genetics , Moscow, Russian Federation.
    Background: Gene fusions are known in many cancers as driver or passenger mutations. They play an important role in both the etiology and pathogenesis of cancer and are considered as potential diagnostic and prognostic markers and possible therapeutic targets. The spectrum and prevalence of gene fusions in thyroid cancer ranges from single cases up to 80%, depending on the specific type of cancer. Read More

    No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
    Diabetes Care 2017 Dec 26. Epub 2017 Dec 26.
    Thyroid Unit, Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
    Objective: To describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial over a 3.5-5-year period.

    Research Design And Methods: Patients (= 9,340) with type 2 diabetes and high risk for cardiovascular events were randomized 1:1 to liraglutide or placebo. Read More

    Bethesda thyroid categories and family history of thyroid disease.
    Clin Endocrinol (Oxf) 2018 Mar 21;88(3):468-472. Epub 2018 Jan 21.
    Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
    Objective: Thyroid cancer is the most common type of endocrine-related cancer worldwide. The aim of this article was to assess the relationship between thyroid diseases diagnosed by fine needle aspiration (FNA) and family history of thyroid disease.

    Design: The study was conducted in a tertiary high-volume thyroid cancer centre. Read More

    Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.
    Clin Nucl Med 2018 Feb;43(2):136-138
    Ga-DOTATATE, a positron-emitting somatostatin analog, has been approved by the Food and Drug Administration for imaging neuroendocrine tumors (NETs). The presence of a second primary malignancy is common in NETs; however, synchronous primary malignancy in the thyroid has rarely been reported. The value of Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogs is an option. Read More

    [Functional diagnostics in endocrinology].
    Internist (Berl) 2018 Jan;59(1):38-47
    Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Campus Innenstadt, Ziemssenstraße 1, 80366, München, Deutschland.
    When investigating many endocrinological diseases, basal laboratory parameters are not sufficient to distinguish between physiological and pathological hormone secretion. Functional diagnostics plays a decisive role in this context. Stimulation and suppression tests are used depending on whether under- or over-function needs to be diagnosed. Read More

    Mediastinal Lymph Node Metastases in Thyroid Cancer: Characteristics, Predictive Factors, and Prognosis.
    Int J Endocrinol 2017 12;2017:1868165. Epub 2017 Nov 12.
    Department of Head & Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
    Background: Mediastinal lymph node metastases (MLNM) have not been extensively studied. The aim of this study is to investigate the characteristics, predictive factors, and prognosis of MLNM in thyroid cancer.

    Methods: This is a retrospective study based on the thyroid cancer patients with MLNM at our institution from 2008 to 2015. Read More

    Ovarian strumal carcinoid - case report.
    Rom J Morphol Embryol 2017 ;58(3):1035-1040
    Department of Obstetrics and Gynecology, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania;
    Strumal carcinoid represents a rare form of ovarian teratoma, consisting of both thyroid tissue and carcinoid structures. The carcinoid component is a well-differentiated neuroendocrine tumor with excellent prognosis. Strumal carcinoid tumors are commonly found in peri-menopausal women who are not usually interested in preserving their fertility and who are thus open to radical surgical treatment. Read More

    Special types of thyroid carcinoma.
    Histopathology 2018 Jan;72(1):40-52
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Perelman School of Medicine, Philadelphia, PA, USA.
    This article reviews the small percentage of thyroid tumours that are not classified as classic papillary thyroid carcinoma, follicular thyroid carcinoma, and medullary thyroid carcinoma. It includes subtypes of papillary thyroid carcinoma, including, tall-cell, hobnail/micropapillary, columnar cell, diffuse sclerosing and solid variants. Poorly differentiated carcinoma, high-grade carcinoma and anaplastic thyroid carcinoma are reviewed. Read More

    Hereditary and familial thyroid tumours.
    Histopathology 2018 Jan;72(1):70-81
    Massachusetts General Hospital, Boston, MA, USA.
    The worldwide incidence of thyroid malignancies has been increasing rapidly. Sensitive imaging modalities and early detection of thyroid lesions have made thyroid cancers the most rapidly increasing cancers in the USA in 2017 (SEER Cancer Facts, 2017). Clinical awareness of potential risk factors, such as inherited thyroid cancers, has allowed earlier recognition of more vulnerable population clusters. Read More

    Initial clinical presentation of single soft tissue metastasis of medullary thyroid carcinoma without primary tumor in the thyroid gland.
    World J Surg Oncol 2017 Dec 13;15(1):221. Epub 2017 Dec 13.
    Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto Nagano, 390-8621, Japan.
    Background: Single soft tissue metastasis of medullary thyroid carcinoma is extremely rare. In addition, several occult medullary thyroid carcinomas with distant metastasis were reported, but undetectable primary lesion at diagnosis was also extremely rare.

    Case Presentation: A 74-year-old man was admitted to our hospital because of a painful nodule in his left buttock for over 1 year. Read More

    Insight into Differentiated Thyroid Cancer Gross Pathological Specimen Shrinkage and Its Influence on TNM Staging.
    Eur Thyroid J 2017 Nov 26;6(6):315-320. Epub 2017 Jul 26.
    Polyclinique Les Fleurs, Service Imagerie Médicale, Ollioules, France.
    Introduction: This study aimed at comparing thyroid cancer staging when taking into account the differences between the "T" assessment" using ultrasound (US) and histopathological measurements.

    Material And Methods: This retrospective study included all consecutive differentiated follicular thyroid cancer (DTC) and medullary thyroid cancer (MTC) patients who underwent postoperative histopathological staging assessment at a single institution. Anaplastic thyroid carcinomas were excluded from the present study. Read More

    Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide.
    Drugs Real World Outcomes 2017 Dec 7. Epub 2017 Dec 7.
    United BioSource Corporation, Blue Bell, PA, USA.
    Background: The risk of pancreatitis and potential risk of medullary thyroid carcinoma associated with glucagon-like peptide-1 receptor agonists prompted the US Food and Drug Administration to require a Risk Evaluation and Mitigation Strategy for albiglutide, including education for prescribers and subsequent assessment of their knowledge of the risks and safe use of albiglutide via a quantitative survey.

    Objective: The objective of this study was to assess prescribers' knowledge of the risks related to medullary thyroid carcinoma, pancreatitis, and the appropriate patient population for albiglutide.

    Methods: Two Risk Evaluation and Mitigation Strategy surveys were conducted 18 months and 3 years after albiglutide was launched. Read More

    Intraoperative calcitonin stimulation testing in the surgical treatment of C-cell disease.
    Neuro Endocrinol Lett 2017 11;38(Suppl1):11-17
    University of Health and Social Work of St.Elisabeth, Bratislava, Slovakia.
    Objective: The prognosis of medullary thyroid carcinoma (MTC), derived from parafollicular C-cells, depends on the completeness of the initial surgical excision. The C-cells produce calcitonin, a peptide hormone used as a biochemical and immunohistochemical tumor marker. The aim of the study was to evaluate an individualized approach to patients with C-cell disease, i. Read More

    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res 2018 Feb 29;24(4):753-765. Epub 2017 Nov 29.
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
    Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously.We monitored toxicities and disease status in patients taking vandetanib for hereditary, advanced MTC. Read More

    Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.
    Oncol Lett 2017 Dec 26;14(6):6485-6496. Epub 2017 Sep 26.
    Division of Pathology Diagnostic Services, Cytology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
    Despite considerable advances in the understanding of thyroid gland biology, correctly diagnosing thyroid nodules and treating high-grade thyroid carcinoma remains challenging. Cancer/testis (CT) antigens have emerged as potential diagnostic tools as well as targets of potential cancer vaccinations. In the present study, a total of 117 patients who underwent surgical therapy for thyroid disease were available for analysis. Read More

    Next-generation panel sequencing identifiesgermline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1.
    Eur J Endocrinol 2018 Feb 20;178(2):K1-K9. Epub 2017 Nov 20.
    Institute for Clinical GeneticsFaculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
    Objective: Our objective was to improve molecular diagnostics in patients with hereditary pheochromocytoma and paraganglioma (PPGL) by using next-generation sequencing (NGS) multi-gene panel analysis. Derived from this study, we here present three cases that were diagnosed withgermline mutations but did not have a prior clinical diagnosis of neurofibromatosis type 1 (NF1).

    Design: We performed genetic analysis of known tumor predisposition genes, including, using a multi-gene NGS enrichment-based panel applied to a total of 1029 PPGL patients. Read More

    Two-stage thyroidectomy in the era of intraoperative neuromonitoring.
    Gland Surg 2017 Oct;6(5):453-463
    Department of Endocrine Surgery, Central Clinic of Athens, Athens, Greece.
    Background: The use of intraoperative neuromonitoring (IONM) provides surgeons with real time information about recurrent laryngeal nerves (RLN) functional integrity. Hence, allowing them to modify the initially scheduled bilateral procedure, to a two-stage thyroidectomy in cases of loss of signal (LOS) on the first side of resection resulting in minimization of bilateral RLN injury. The purpose of our study was to present our results since the implementation of the above mentioned process in both malignant and benign thyroid disease. Read More

    Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma.
    Endocr Relat Cancer 2018 Feb 15;25(2):145-162. Epub 2017 Nov 15.
    Institute for Diabetes and CancerHelmholtz Zentrum München, Neuherberg, Germany
    Rats affected by the MENX syndrome spontaneously develop multiple neuroendocrine tumors (NETs) including adrenal, pituitary and thyroid gland neoplasms. MENX was initially reported to be inherited as a recessive trait and affected rats were found to be homozygous for the predisposingmutation encoding p27. We here report that heterozygous MENX-mutant rats (p27+/mut) develop the same spectrum of NETs seen in the homozygous (p27mut/mut) animals but with slower progression. Read More

    Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.
    Endocr Relat Cancer 2018 Feb 15;25(2):T1-T13. Epub 2017 Nov 15.
    Genetics BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Medullary thyroid carcinoma (MTC), a tumor derived from the neural crest, occurs either sporadically or as the dominant component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B. The discovery that mutations in theprotooncogene cause hereditary MTC was of great importance, since it led to the development of novel methods of diagnosis and treatment. For example, the detection of a mutatedallele in family members at risk for inheriting MEN2A or MEN2B signaled that they would develop MTC, and possibly other components of the syndromes. Read More

    1 OF 141